Companies in Hematology
There are 452 companies in Hematology which include STAR Therapeutics, Keros Therapeutics, Hemosonics, Ajax, Shield Therapeutics. 289 companies in Hematology are funded, with 143 having secured Series A funding. Till date, the sector has seen the creation of 2 Unicorns. United States has the most number of companies in Hematology (191), followed by United Kingdom
(39), and then China (26).
2026 has seen the creation of 3 Hematology companies. On average, the last 10 years have seen 14 new companies launched every year. Most number of Hematology startups have been founded by alumni from Stanford University, Harvard University and Massachusetts Institute of Technology.
Here is a List of top companies in Hematology
Developer of antibody therapies for multiple diseases. The company is developing antibody drug discovery to generate drug programs that target multiple diseases with a single therapy. Its lead candidate ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders. The company is addressing drugs for immunology, immuno-oncology, and rare hematologic diseases.
Key facts about STAR Therapeutics
- Founded Year: 2018
- Location: San Francisco (United States)
- Stage: Series D
- Total Funding till date: $215M
- Investors: Sanofi Ventures, Sofinnova Investments and 18 Others
- Latest Funding Round: Series D, Sep 30, 2025, $*****
- Tracxn Score: 67/100 What is this?
- Competitors Rank: 32 of 3,140 Competitors
Keros Therapeutics is developing small molecules and biologics for rare neuromuscular and hematologic diseases. The product pipeline involves KER-050 to treat myelodysplastic syndrome and myelofibrosis (phase II); KER-047 to treat hepcidin-cased anemia and fibrodysplasia ossificans progressive (FOP); KER-012 to treat pulmonary arterial hypertension and bone disorders.
Key facts about Keros Therapeutics
- Founded Year: 2016
- Location: Lexington (United States)
- Stage: Public
- Total Funding till date: $90M
- Investors: Foresite Capital, Orbimed and 9 Others
- Latest Funding Round: Series C, Mar 04, 2020, $*****
- Tracxn Score: 66/100 What is this?
- Competitors Rank: 40 of 3,641 Competitors
3. Hemosonics
Developer of viscoelastic testing systems for hemostasis assessment and bleeding management. The company provides analyzers, cartridges, and quality control kits for point-of-care and laboratory use. These systems evaluate blood coagulation properties to assess hemorrhage and thrombosis risk. The technology supports clinical conditions in surgery, trauma, liver transplantation, and obstetric procedures. External quality assessment proficiency testing programs are also available.
Key facts about Hemosonics
- Founded Year: 2004
- Location: Charlottesville (United States)
- Stage: Acquired
- Total Funding till date: $24.9M
- Investors: National Heart Lung and Blood Institute, U.S. Air Force and 1 Other
- Latest Funding Round: Series B, Feb 14, 2017, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 1 of 22 Competitors
4. Ajax
Developer of targeted therapies for the treatment of hematologic malignancies. The company is developing small molecule therapeutics targeting key cytokine signaling pathways. The computational drug discovery platform combines deep disease, genetics, and structural biology.
Key facts about Ajax
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Acquired
- Total Funding till date: $135M
- Investors: EcoR1, Goldman Sachs Asset Management and 8 Others
- Latest Funding Round: Series C, May 13, 2024, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 3 of 106 Competitors
Developer of pharmaceuticals to treat iron deficiency anemia and hyperphosphatemia. Its lead products are Feraccru is a stable, non-salt-based oral therapy for adults with iron deficiency. Also, has other drug candidates which include PT20 which is an iron-based phosphate binder to treat patients with hyperphosphatemia related to dialysis and chronic kidney disease, PT30 for hypo-allergenic IV iron therapy, and PT40 first generic version of iron sucrose.
Key facts about Shield Therapeutics
- Founded Year: 2008
- Location: Gateshead (United Kingdom)
- Stage: Public
- Total Funding till date: $58.9M
- Investors: Inventages and AOP Health
- Latest Funding Round: Post IPO, Sep 28, 2023, $*****
- Tracxn Score: 63/100 What is this?
- Competitors Rank: 66 of 3,061 Competitors
